Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL

Drug Category: Array
Conference Category: Array
Lead Author: Mato A, et al.
Published Date: 10/12/2017
Download Link: /wp-content/uploads/2019/03/ASH%202017%20Mato%20Pembro%20Final.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top